(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.11%.
Vistagen Therapeutics's earnings in 2025 is -$51,418,000.On average, 3 Wall Street analysts forecast VTGN's earnings for 2026 to be -$52,580,140, with the lowest VTGN earnings forecast at -$68,229,095, and the highest VTGN earnings forecast at -$36,738,744.
In 2027, VTGN is forecast to generate -$56,857,579 in earnings, with the lowest earnings forecast at -$64,438,590 and the highest earnings forecast at -$49,276,569.